LAMEA DNA Diagnostics Market By Product Type (Instruments, Reagents, Service & Software), Application (Oncology, Infectious Disease Testing, Myogenic Disorder Diagnosis, Clinical Confirmation, Prenatal Diagnosis, Pre-implantation), Technology (PCR, Microarrays, In situ hybridization, Sequencing Technology, Mass Spectrometry), End User
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA DNA Diagnostics Market
Market Report Description
The LAMEA DNA Diagnostics Market is expected to grow at a CAGR of 13.4% during 2016 -2022. The development of personalized medicine is solely dependent on the rapid diagnosis at the point of care; therefore, leading pharmaceutical companies are collaborating with diagnostic companies to provide personalised medicine. The convergence of different technologies would eventually drive the DNA diagnostic market growth. The recent technological developments in DNA diagnostics include next generation sequencing and PCR technology. Next generation sequencing technology has made whole genome sequencing cost effective and technically feasible.
The Brazil market dominated the LAMEA DNA Diagnostics Market in 2015, and would grow at a CAGR of 12.8% during the forecast period. The UAE market is expected to grow at CAGR of 12.1% during 2016-2022. The Sequencing Technology market contributed the larger revenue to the LAMEA DNA Diagnostics Market in 2015. The Microarrays market is expected to attain a market size of $462.6 million by 2022. However, In situ hybridization market is expected to grow at CAGR of 14.7% during 2016-2022. The report highlights the adoption of DNA Diagnostics in LAMEA region. Based on the Product Types, the LAMEA DNA Diagnostics Market is segmented into Instruments, Reagents and Service & software segment.
Based on the Application, the market is bifurcated into Oncology, Infectious disease testing, Myogenic disorder diagnosis, Clinical confirmation diagnostics, Prenatal diagnosis, Pre-implantation diagnostics and other segments. Based on the Technology, the market is bifurcated into PCR, Microarrays, In situ hybridization, Sequencing Technology, Mass Spectrometry and other segments. Further, the market is segmented into POC (Point-of-Care), Central Laboratories and Self-Testing segments based on the End Users. The countries included in the report are Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria and Rest of LAMEA.